Skip to main content

Advertisement

SpringerLink
Log in

Rationale for the use of clodronate in osteoporosis

  • Published:
Osteoporosis International Aims and scope Submit manuscript

Abstract

Bisphosphonates are widely used in disorders associated with increased resorption of bone, particularly in Paget's disease of bone and in the hypercalcemia of malignancy. Because of their undoubted efficacy and relatively low toxicity, bisphosphonates are attractive candidates for the management of osteoporosis. Clodronate, one of the many bisphosphonates being tested in osteoporosis, may be given intravenously or by mouth. In contrast to etidronate, even high doses of clodronate do not impair the mineralization of bone, making it suitable for long-term use in osteoporosis. As do all the bisphosphonates tested thus far, clodronate appears to delay the rate of bone loss in osteoporosis. Long-term studies are relatively few, so that its steady-state effects on bone mass are not yet known. Most data suggest clodronate is capable at least of delaying the rate of bone loss, but several pilot studies with this agent suggest that increments of bone mass might be sustainable for several years. Clodronate is likely to decrease the frequency of osteoporotic fractures, but there is no evidence for this at present. Well-controlled, long-term prospective studies are needed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Fleisch H. Bisphosphonates: history and experimental basis. Bone 1987; 8(Suppl):523–8.

    Google Scholar 

  2. Douglas DL, Duckworth T, Kanis JA, et al. Biochemical and clinical responses to dichloromethylene diphosphonate in Paget's disease of bone. Arthritis Rheum 1980; 23:1185–92.

    Google Scholar 

  3. Kanis JA. Pathophysiology and treatment of Paget's disease of bone. London: Martin Dunitz, 1991.

    Google Scholar 

  4. Jung A. Comparison of two parenteral disphosphonates in hypercalcemia of malignancy. Am J Med 1982; 72:221–6.

    Google Scholar 

  5. Percival RC, Paterson AD, Yates AJP, et al. Treatment of malignant hypercalcaemia with clodronate. Br J Cancer 1985; 51:665–9.

    Google Scholar 

  6. Urwin GH, Yates AJP, Gray RES, et al. Treatment of hypercalcaemia of malignancy with intravenous clodronate. Bone 1987; 8(Suppl):43–51.

    Google Scholar 

  7. Elomaa I, Blomqvist C, Porkka L, Lamberg-Allardt C, Borgstrom GH. Treatment of skeletal disease in breast cancer. A controlled clodronate trial. Bone 1987; 8 (Suppl):53–6.

    Google Scholar 

  8. Delmas PD, Charhon S, Chapuy MC, et al. Long-term effects of dichloromethylene diphosphonate (CL2 MDP) on skeletal lesions in multiple myeloma. Metab Bone Dis Rel Res 1982; 4:163–8.

    Google Scholar 

  9. Paterson AHG, Powles TJ, Kanis JA, McCloskey E, Hanson J, Ashley S. Oral clodronate decreases skeletal morbidity in patients with bone metastases for breast cancer. A double-blind controlled trial. J Clin Oncol 1992. In press.

  10. Parfitt AM. The physiologic and clinical significance of bone histomorphometric data. In: Recker R, ed. Bone histomorphometry: techniques and interpretation. Boca Raton, Fl.: CRC Press, 1982:143–223.

    Google Scholar 

  11. Erickson EF. Normal and pathological remodeling of human trabecular bone: three dimensional reconstruction of the remodeling sequence in normals and in metabolic bone disease. Endocrine Rev 1986; 7:379–408.

    Google Scholar 

  12. Kanis JA. Treatment of osteoporotic fracture. Lancet 1984; i:27–33.

    Google Scholar 

  13. Frost HM. Presence of microscopic cracks in bone. Henry Ford Hosp Bull 1960; 8:25–35.

    Google Scholar 

  14. Kanis JA. The restoration of skeletal mass. A theoretic overview. Am J Med 1991; 91(5b):29–36.

    Google Scholar 

  15. Aaron JE, Francis RM, Peacock M, Makins NB. Contrasting microanatomy of idiopathic and corticosteroid-induced osteoporosis. Clin Orthop 1989; 243:294–305.

    Google Scholar 

  16. Anderson C, Cape RDT, Crilly RG, Hodsman AB, Wolfe BMJ. Preliminary observation of a form of coherence therapy for osteoporosis. Calcif Tissue Int 1984; 36:341–43.

    Google Scholar 

  17. Watts NB, Harris ST, Genant HK, Wasnich R, Miller PD. Intermittent cyclical etidronate treatment in postmenopausal osteoporosis. N Engl J Med 1990; 323:73–9.

    Google Scholar 

  18. Storm T, Thamsborg G, Steiniche T, Genant HK, Sorensen OHN. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 1990; 322:1265–71.

    Google Scholar 

  19. Chesnut CH. Synthetic calcitonin, diphosphonates and anabolic steroids in the treatment of postmenopausal osteoporosis. In: Christiansen C, Arnaud CD, Nordin BEC, Parfitt AM, Peck WA, Riggs BL, eds. Copenhagen: Osteopress 1984:594–55.

    Google Scholar 

  20. Papapoulos SE, Landman, JO, Bijvoet OLM, et al. The use of bisphosphonates in the treatment of osteoporosis. Bone 1992; 13(Suppl):41–9.

    Google Scholar 

  21. Reginster JY, Deroisy R, Denis D, et al. Prevention of postmenopausal bone loss by tiludronate. Lancet 1989; ii:1469–71.

    Google Scholar 

  22. Devogelaer JP, Nagant de Deuxchaisnes C. Treatment of involutional osteoporosis with the bisphosphonate APD (disodium pamidronate); non-linear increase of lumbar bone mineral density. J Bone Miner Res 1990; 5(Suppl 12):S251.

    Google Scholar 

  23. Parfitt AM. Morphological basis of bone mineral measurements: transient and steady-state effects of treatment in osteoporosis. Miner Elect Metab 1980; 4:273–87.

    Google Scholar 

  24. Kanis JA, Caulin F, Russell RGG. Problems in the design of clinical trials in osteoporosis. In: St J Dixon A, Russell RGG, Stamp TCB, eds. Osteoporosis: a multidisciplinary problem. Royal Society of Medicine. Int Congr Symp Series 55; 1983:205–22.

  25. Yates AJP, Jones TH, Mundy KI, et al. Immobilisation hypercalcaemia in adults and treatment with clodronate. Br Med J 1984; 289:1111–12.

    Google Scholar 

  26. Minaire P, Berard E, Meunier PJ, Edouard C, Goedert G, Pilonchery G. Effects of disodium dichloromethylene diphosphonate on bone loss in paraplegic patients. J Clin Invest 1981; 68:1086–92.

    Google Scholar 

  27. Minaire P, Depassio J, Barard E, et al. Effects of clodronate on immobilisation bone loss. Bone 1987; 8 (Suppl):63–8.

    Google Scholar 

  28. Elomaa I, Blomqvist C, Porkka L, Holmstrom T. Experience of clodronate in treatment of multifocal eosinphilic granuloma of bone. J Intern Med 1989; 225:59–61.

    Google Scholar 

  29. Cundy T, Beneton MNC, Darby AJ, Marshall WJ, Kanis JA. Osteopenia in systemic mastocytosis: natural history and responses to treatment with inhibitors of bone resorption. Bone 1987; 8:149–55.

    Google Scholar 

  30. McCloskey EV, Beneton MNC, O'Rourke N, Eyres K, O'Doherty D, Kanis JA. The effect of phosphate and intermittent clodronate in post-menopausal osteoporosis. In: Christiansen C, Overgaard K, eds. Osteoporosis 1990. Copenhagen: Osteopress, 1990: 1401–2.

    Google Scholar 

  31. Aaron JE, DeVernejoul MC, Kanis JA. The effect of sodium fluoride on trabecular architecture in osteoporosis. Bone 1991; 12:307–10.

    Google Scholar 

  32. Flora L, Hassing GS, Parfitt AM, Villanueva AR. Comparative skeletal effects of two diphsophonates in dogs. Metab Bone Dis Rel Res 1980; 2:389–407.

    Google Scholar 

  33. Steiniche T, Hasling C, Thamsborg G, et al. A histomorphometric analysis of iliac crest bone biopsies from patients treated with intermittent cyclical etidronate therapy for postmenopausal osteoporosis. In: Christiansen C, Johansen JS, Riis BJ, eds. Osteoporosis 1977. Copenhagen: Osteopress, 1977: 1182–7.

    Google Scholar 

  34. Preston CJ, Yates AJP, Beneton MNC, et al. Effective short-term treatment of Paget's disease with oral etidronate. Br Med J 1986; 292:79–80.

    Google Scholar 

  35. McCloskey EV, Yates AJP, Beneton MNC, Galloway J, Harris S, Kanis JA. Comparative effects of intravenous diphosphonates on calcium and skeletal metabolism in man. Bone 1987; 8(Suppl):35–41.

    Google Scholar 

  36. Bruickman PM, Biggemann M, Hilweg D. Prediction of the compressive strength of human lumbar vertebrae. Spine 1989; 14:606–10.

    Google Scholar 

  37. Kanis JA. What constitutes efficacy in studies of osteoporosis. Drugs Ageing. In press.

Download references

Author information

Authors and Affiliations

  1. WHO Collaborating Centre for Metabolic Bone Disease, Department of Human Metabolism and Clinical Biochemistry, University of Sheffield, Beech Hill Road, S10 2RX, Sheffield, UK

    J. A. Kanis, E. V. McCloskey, P. Sirtori, S. Khan, D. Fern, K. Eyres, J. Aaron & M. N. C. Beneton

Authors
  1. J. A. Kanis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E. V. McCloskey
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P. Sirtori
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S. Khan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D. Fern
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. K. Eyres
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J. Aaron
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M. N. C. Beneton
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kanis, J.A., McCloskey, E.V., Sirtori, P. et al. Rationale for the use of clodronate in osteoporosis. Osteoporosis Int 3 (Suppl 2), 23–28 (1993). https://doi.org/10.1007/BF01623223

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01623223

Keywords

Search

Navigation